Question 1

What’s the financial overview for Kyverna Therapeutics, Inc.?

Accepted Answer

Kyverna Therapeutics, Inc.’s market cap stands at $0.00 trillion right now. The company’s trailing twelve-month earnings per share EPS is $-3.24, with a dividend yield of N/A%. Their next earnings report is set for January 29, 2025, and the estimated EPS for that period is $1.61. You can also check out summaries of their income statement, balance sheet, and cash flow details for a fuller picture of their financials.

Question 2

How can I analyze historical data?

Accepted Answer

To analyze historical data with AI tools, apply the date range filter above the table to focus on a specific period. The table displays daily open, high, low, close prices, and volume, enabling you to spot trends and patterns. Use these insights to make informed decisions based on historical performance.

Question 3

What does Kyverna Therapeutics, Inc. Stock ROE tell us?

Accepted Answer

Kyverna Therapeutics, Inc. stock ROE shows positive market sentiment. A higher ROE means the company’s management is doing a better job at using equity financing to drive income and growth. It’s a handy metric for comparing how a company stacks up against its competitors or the broader market.

Question 4

What do Analysts say about Kyverna Therapeutics, Inc.?

Accepted Answer

3 number of Analysts recommended buying Kyverna Therapeutics, Inc. the stock and 0 analysts recommended selling the stock.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024
Revenue	$0.00	$0.00	$0.00	$0.00
Cost of Revenue	$0.00	$0.00	$530000.00	$482000.00
Gross Profit	$0.00	$0.00	-$530000.00	-$482000.00
Gross Profit Ratio
R&D Expenses	$32.92M	$29.19M	$27.32M	$22.48M
SG&A Expenses	$7.56M	$9.58M	$6.11M	$6.88M
Operating Expenses	$41.04M	$38.77M	$33.44M	$29.36M
Total Costs & Expenses	$41.04M	$38.77M	$33.44M	$29.36M
Interest Income	$3.58M	$4.36M	$4.69M	$2.73M
Interest Expense	$27000.00	$32000.00	$39000.00	$44000.00
Depreciation & Amortization	$563000.00	$558000.00	$530000.00	$482000.00
EBITDA	-$36.90M	-$33.90M	-$28.23M	-$26.17M
EBITDA Ratio
Operating Income	-$41.04M	-$38.77M	-$33.44M	-$29.36M
Operating Income Ratio
Other Income/Expenses (Net)	$3.55M	$4.28M	$4.63M	$2.67M
Income Before Tax	-$37.49M	-$34.49M	-$28.80M	-$26.69M
Income Before Tax Ratio
Income Tax Expense	$0.00	$0.00	$0.00	$18000.00
Net Income	-$37.49M	-$34.49M	-$28.80M	-$26.69M
Net Income Ratio
EPS	-$0.92	-$0.80	-$0.67	-$1.12
Diluted EPS	-$0.92	-$0.80	-$0.67	-$1.12
Weighted Avg Shares Outstanding	$43.21M	$43.16M	$43.13M	$23.75M
Weighted Avg Shares Outstanding (Diluted)	$43.21M	$43.16M	$43.13M	$23.75M

Kyverna Therapeutics, Inc.